Regulus Therapeutics director to retire
Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share
Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet
Regulus Therapeutics Inc. said director Mark Foletta will retire from the board upon the expiration of his current term ending at the 2018 annual meeting of stockholders.
The San Diego, Calif.-based company said Foletta's decision was a result of his concurrent service as the executive vice president and CFO for cancer drug developer Tocagen Inc.
